GENEVA, 9 Feb – RIA Novosti, Elizaveta Isakova. The World Health Organization expects Sputnik V to be among the vaccines distributed under the COVAX program. “We hope that the Gamaleya SIC vaccine will join COVAX, provided that it (the vaccine) is included in the list of drugs recommended by WHO for use in emergencies, “the organization's press service told RIA Novosti.
On the eve of the WHO held regular discussions about additional data on the Russian vaccine. Another discussion is scheduled for February 15th.
COVAX is an international mechanism launched by WHO in partnership with the Global Alliance for Vaccines and Immunization (GAVI) and the Coalition for Epidemic Preparedness Innovation. Under the terms of the program, high-income countries pay for the purchase of vaccines, thereby subsidizing the so-called funded states. COVAX has now entered into agreements with Pfizer / BioNTech and AstraZeneca to supply vaccines for equitable distribution to member countries.
Last week, the scientific journal Lancet published the results of the third phase of clinical studies of “Sputnik V”, confirming its high efficiency and safety: the vaccine fully protects against the severe course of COVID-19.
Sputnik V is the world's first drug for the prevention of coronavirus infection. It was developed at the Gamaleya Center in conjunction with the Russian Direct Investment Fund on a studied and proven platform of human adenoviral vectors.
In August, the Ministry of Health registered the vaccine, and a civil vaccination campaign started in Russia in December.
In addition to Russia, the use of Sputnik V has already been approved in Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua and Republika Srpska (the Bosnia and Herzegovina), Lebanon and Myanmar.